SERENGEN has been established in June 2019 with a novel DNA-encoded library technology, which was developed at the TU Dortmund University, Germany. The platform represents a step-change in the synthesis of DNA-encoded libraries. For the first time, a broad range of modern organic synthesis methods can be applied in the presence of DNA to construct drug-like scaffolds in a combinatorial approach. Hence, we will deliver truly drug-like hits that are amenable to modern medicinal chemistry accelerating chemical lead generation and optimization.
Customized DNA-Encoded Libraries
SERENGEN designs DNA-encoded libraries according to customer's needs. A chemistry validation phase consisting of the three stages: chemistry development, reaction optimization and reaction scoping is followed by the production of the customized DEL. Several exclusivity options are available.
DNA-Encoded Library Screening
SERENGEN screens DELs against an immobilized protein target. Such DELs can be selected from our DEL collection or can be provided by the client. Hits are identified through their DNA tag after PCR amplification, DNA sequencing and enrichment calculation. Following on- and off-DNA single molecule syntheses and screening, the chemical structure of a pre-agreed number of hits is disclosed. Several exclusivity options are available.
If we raised your interest please contact us at
SERENGEN is located at the Science and Technology Campus Dortmund, Germany. With more than 300 high-tech companies and 10,000 employees, this hub is one of the top 5 high-tech addresses in Europe. We are in the immediate vicinity of the Technical University of Dortmund, the Leibniz Institute for Analytical Sciences (ISAS), the Leibniz Research Centre for Working Environment and Human Factors (IfADo) and the Max Planck Institute for Molecular Physiology (MPI).